Greystone Associates, March 2011
share, and provides forecaststo 2015
- Profiles sustained release technology participants, their product development activities, business strategies, and corporate alliances and affiliatio Executive
Jain PharmaBiotech, May 2012, Pages: 633
known to have a neuroprotective effect. With the approval of new products and takeover of markets for obsolete symptomatic therapies, the neuroprotection market value will rise by the year 2016 when it
Life Science Intelligence, Inc., Jan 2011
methods for early detection of age-related maculardegeneration, diabetic maculopathy, and other types of retinal disease in the human eye
- Portable diagnostic device used to determine the presence and
Life Science Intelligence, Inc., Jan 2012, Pages: 101
- Ready-to-market medical device for assessing - via the eye - exposure to neurotoxins, cyanide, and low level radiation. Future products include assessment of mild TBI and other health conditions
Life Science Intelligence, Inc., Dec 2009, Pages: 1763
with high bioavailability
- Monitoring system to replace the manual assessment of labor progress with real-time/continuous information
- Device for the treatment of Barrett's esophagus and prevention
Life Science Intelligence, Inc., July 2007
acute spinal cord injury, cancer, maculardegeneration, and glaucoma
Company 244 - Nitric oxide-based therapies to accelerate healing of tendon, bone, and other musculoskeletal tissue
Company 245
Global Industry Analysts, Inc., Oct 2010, Pages: 562
Middle East, and Latin America. Annual estimates andforecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 142
